WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010028673) USE OF A PEPTIDE AS A THERAPEUTIC AGENT
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/028673    International Application No.:    PCT/EP2008/007679
Publication Date: 18.03.2010 International Filing Date: 09.09.2008
IPC:
A61K 38/22 (2006.01), A61P 31/06 (2006.01), A61P 31/20 (2006.01), A61P 3/00 (2006.01), A61P 9/00 (2006.01), A61P 11/00 (2006.01), A61P 25/28 (2006.01), A61P 31/00 (2006.01), A61P 35/00 (2006.01), A61P 37/00 (2006.01)
Applicants: MONDOBIOTECH LABORATORIES AG [LI/LI]; Herrengasse 21 FL-9490 Vaduz (LI) (For All Designated States Except US).
BEVEC, Dorian [DE/DE]; (DE) (For US Only).
CAVALLI, Fabio [CH/CH]; (CH) (For US Only).
CAVALLI, Vera [CH/CH]; (CH) (For US Only).
BACHER, Gerald [DE/DE]; (DE) (For US Only)
Inventors: BEVEC, Dorian; (DE).
CAVALLI, Fabio; (CH).
CAVALLI, Vera; (CH).
BACHER, Gerald; (DE)
Agent: ARTH, Hans-Lothar; ABK, Jasminweg 9, 14052 Berlin (DE)
Priority Data:
Title (EN) USE OF A PEPTIDE AS A THERAPEUTIC AGENT
(FR) UTILISATION D’UN PEPTIDE EN TANT QU’AGENT THÉRAPEUTIQUE
Abstract: front page image
(EN)The present invention is directed to the use of the peptide compound Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-D-Arg-Pro-Lys-Pro-Gln-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-D-Arg-Pro-Lys-Pro-Gln-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
(FR)La présente invention concerne l’utilisation du composé peptidique Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-D-Arg-Pro-Lys-Pro-Gln-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2 en tant qu’agent thérapeutique pour la prophylaxie et/ou le traitement du cancer, de maladies auto-immunes, de maladies fibrotiques, de maladies inflammatoires, de maladies neurodégénératives, de maladies infectieuses, de maladies pulmonaires, de maladies cardiaques et vasculaires et de maladies métaboliques. La présente invention concerne en outre des compositions pharmaceutiques de préférence sous la forme d’un lyophilisat ou d’une solution tampon liquide ou d’une formulation de lait maternel artificiel ou d’un substitut de lait maternel contenant le peptide Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-D-Arg-Pro-Lys-Pro-Gln-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2 facultativement conjointement à au moins un véhicule, un cryoprotecteur, un lyoprotecteur, un excipient et/ou un diluant pharmaceutiquement acceptables.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)